193 results about "RSV Infections" patented technology

The invention relates to an anti-RSV polypeptide membrane fusion inhibitor as well as a preparation method and application thereof. The invention discloses a compound, a pharmaceutical salt or a derivative thereof, a pharmaceutical composition and a preparation product containing the compound, and application of the compound and the pharmaceutical salt or the derivative in preparation of medicines for preventing and / or treating diseases caused by RSV or other paramyxoviridae viruses. The polypeptide disclosed by the invention shows the anti-RSV activity and safety which are obviously superior to those of positive control polypeptide. Molecular interaction experiments show that the polypeptide acts on the NHR region of the RSV F protein, and the fusion of the RSV virus and a target cell is prevented by forming an inactive six-helix structure with NHR, or by destroying the RSV NHR structure and inhibiting the process of forming a six-helix bundle by NHR and CHR in the F protein in the key step of RSV infection.

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of RSV infection.

The invention discloses an RSV infection immortalized tree shrew aorta vascular endothelial cell model, and particularly relates to a method for separating and culturing primary aorta vascular endothelial cells from tree shrew aorta, further establishing an immortalized tree shrew aorta vascular endothelial cell line, taking the cell line as an RSV virus culture medium, and constructing an RSV infection immortalized tree shrew aorta vascular endothelial cell model. Establishing an RSV infected immortalized tree shrew aortic vascular endothelial cell model, and preparing a high-infection-titer RSV virus; the invention provides key support for preparation and detection of RSV virus and construction of a tree shrew in-vivo infection model, provides a stable virus source for development of comparative medical research or vaccine evaluation, and has far-reaching significance for deep exploration of RSV pathogenic mechanism, drug and vaccine evaluation and the like.

Provided is a mutant of a respiratory syncytial virus (RSV) pre-fusion conformational F protein. The mutant comprises an amino acid mutation relative to the amino acid sequence of a wild-type RSV F protein, the amino acid mutation being amino acids at a position 392 and a position 493 or a position near the position 493 being substituted by C, and a disulfide bond being formed between a position 392C and a position 493C or a position near the position 493C after the mutation. Also provided are a related DNA coding sequence, recombinant plasmid and mRNA sequence and a corresponding RSV vaccine. By introducing a disulfide bond at a suitable position, and combining same with cavity filling, electrostatic mutation, proline mutation and the like, the expression and stability of an F protein having pre- and post-fusion conformations and a trimerized conformation are significantly improved, and the conformation of the F protein is significantly inhibited from being converted into the post-fusion conformation. The mutant is also applied to preparation of an RSV vaccine and RSV infection detection.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The present invention provides mutant RSV F molecules that can be, or are, stabilized in the pre-fusion conformation (preF) by the introduction of one or more dityrosine (DT) crosslinks. The present invention also provides methods of making such mutant RSV F molecules, vaccine compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods to protect subjects against RSV infection.

Highly potent respiratory syncytial virus (RSV) neutralizing monoclonal antibodies that specifically bind RSV fusion protein (F) or RSV attachment glycoprotein (G) are described. The monoclonal antibodies were synthesized by sequencing RSV G- and RSV F-specific B cells from a human participant of an RSV challenge study. The RSV-specific monoclonal antibodies described herein exhibit potent neutralization of RSV (IC50 as low as 0.4 ng / ml) that is superior to previously disclosed RSV neutralizing antibodies. The RSV-specific monoclonal antibodies can be used, for example, to treat, inhibit and detect RSV infection.

The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and / or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.

The present disclosure provides immunogenic compositions comprising RSV and VZV antigens, as well as their use in the prevention and / or treatment of VZV and RSV infections.

The invention belongs to the technical field of medicines, and discloses application of an adeno-associated virus vector in preparation of medicines for preventing and treating RSV infection and / or diseases caused by RSV. According to the invention, a recombinant adeno-associated virus vector is adopted for the first time to construct a medicine for preventing and treating RSV infection or diseases caused by RSV infection, and based on this, the invention provides a nucleic acid molecule which comprises: (a1) a first region which comprises a first adeno-associated virus inverted terminal repeat sequence, and (a2) a second region which comprises a second adeno-associated virus inverted terminal repeat sequence; and (a2) a second region comprising a gene encoding a respiratory syncytial virus antigen; the recombinant adeno-associated virus containing the nucleic acid molecule can generate better humoral immune effect and cellular immune effect, has a certain serum neutralization effect on strains of A and B subtypes of RSV, and particularly, when the antigen is a fusion protein of the respiratory syncytial virus or a fusion protein mutant of the respiratory syncytial virus, the recombinant adeno-associated virus has a certain serum neutralization effect on the strains of A and B subtypes of the RSV. The recombinant adenovirus vector containing the nucleic acid molecule can successfully realize the expression of the F protein before RSV fusion.

The invention discloses a nano antibody of pre-F protein of a targeted respiratory syncytial virus and application of the nano antibody. The nano antibody comprises a heavy chain variable region, and the heavy chain variable region comprises heavy chain complementary determining regions CDR1, CDR2 and CDR3. The nano antibody disclosed by the invention can be specifically combined with RSV, and has a good application prospect in the aspect of RSV infection related diseases.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The present application provides an anti-RSV antibody or antigen-binding fragment thereof and application thereof. Specifically, an anti-RSV antibody or antigen-binding fragment thereof capable of effectively neutralizing / binding human RSV envelope protein is provided. The present application also provides an antibody drug conjugate comprising the antibody or antigen-binding fragment, which can be applied to the preparation of a medicament for preventing and / or treating RSV infection, and has a good application prospect.

The application belongs to the technical field of biological medicine, and particularly relates to a RSV pre-fusion F protein mutant and application thereof. The RSV pre-fusion F protein mutant has good stability, high expression and / or immunogenicity, and can be used for preparing a RSV antibody, preventing RSV infection, preventing and / or treating a disease caused by RSV infection, detecting the presence or content of the RSV antibody in a sample, diagnosing RSV infection, and diagnosing a disease caused by RSV infection.

The invention relates to the technical field of medical data processing, in particular to a risk assessment method and system for RSV infection. A risk assessment method for RSV infection comprises the following steps: S1, constructing a PM2.5 land utilization regression model, and obtaining the real-time concentration of PM2.5 in a target area by using the PM2.5 land utilization regression model; s2, obtaining related influence data, and obtaining the correlation between the PM2.5 exposure and the related influence data of the children with respiratory diseases caused by RSV infection according to the related influence data; and S3, according to the correlation, determining the mediation effect of the immune function change in the respiratory diseases caused by the PM2.5 exposure to the RSV infection. By prospectively researching the correlation between PM2.5 exposure and related influence data of children with respiratory diseases caused by RSV infection, the reliability and scientificity are improved.

The invention relates to an application of a PROTAC compound targeting M2-1 protein in preparation of an anti-RSV (Respiratory Syndrome Virus) drug, and belongs to the technical field of biological medicines. According to the invention, by constructing bifunctional micromolecules capable of simultaneously combining the M2-1 protein and CRBN E3 ubiquitin ligase, selective degradation of the M2-1 protein is realized, the limitation that the protein cannot be effectively targeted in the prior art is broken through, and a new technical approach is provided for solving the problems of single target spot, high drug resistance risk, lack of specific drugs and the like in RSV infection treatment; the method has obvious novelty and substantial progress.

A phospholipid-rich milk fraction for use in the prevention of viral infection of respiratory syncytial virus (RSV) and / or in the further development of the prevention of viral infection of respiratory syncytial virus (RSV) is disclosed.

Provided are an antigen-binding protein neutralizing respiratory syncytial virus (RSV) and a use thereof. The antigen-binding protein comprises a single-domain antibody containing CDR1, CDR2, and CDR3 antigen complementarity-determining regions, and has the function of exerting virus-neutralizing activity by recognizing and binding to RSV surface proteins. The antigen-binding protein can prevent or treat diseases caused by RSV infection.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

To provide antigenic multimeric respiratory syncytial virus (RSV) G polypeptides for use in eliciting an immune response to RSV.SOLUTION: Provided is an antigenic RSV G polypeptide comprising more than two RSV Gcc monomers, where the polypeptide does not comprise ferritin. Also provided is a method of eliciting an immune response to RSV or protecting a subject against RSV infection, comprising the step for administering the antigenic RSV G polypeptide or composition to a subject.SELECTED DRAWING: None

The invention relates to shape-specific cerium oxide nanoparticles (CNPs). methods of preparing CNPs. and methods of using CNPs to treat and / or inhibit and / or reduce and / or reverse the complications of respiratory syncytial virus (RSV) disease and other infections that cause pathologic immune responses. through the balance of favorable immunomodulation and reduced lung immunopathology. CNPs have the capability to switch between Ce3+ and Ce4+ oxidation states (e.g., to scavenge reactive oxygen species). The shape-specific CNPs are synthesized into various shapes and sizes. These properties offer an opportunity to utilize CNPs to modulate macrophage phenotypes along the spectrum of M1 and M2 phenotypes to combat RSV infection and other infections that cause pathologic immune responses.

The present invention provides an immunogenic composition comprising recombinant peptides and proteins, the recombinant peptides and proteins comprising respiratory syncytial virus (RSV) viral antigens and immunogens, such as RSV F protein peptides. The immunogenic composition comprises a secreted fusion protein comprising a soluble RSV viral antigen, which is linked to the collagen C-terminal portion by in-frame fusion to form a disulfide-linked trimeric fusion protein. The immunogenic composition can be used to generate an immune response, such as for treating or preventing RSV infection. The immunogenic composition can be used in vaccine compositions, such as as part of a preventive and / or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prevention, treatment and / or diagnostic methods, and related kits.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of prevention and treatment of RSV (Respiratory Syndrome Virus). Specifically, the invention provides a monoclonal antibody capable of specifically binding to a neoepitope on pre-F protein, and application of the monoclonal antibody to detection, prevention and / or treatment of RSV infection and / or diseases caused by the infection.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

The present invention relates to vaccination against respiratory syncytial virus (RSV), in particular to the use of a vaccine formulation comprising an RSV F fusion protein (RSV F protein) antigen and an adjuvant in methods of prevention of RSV infection and disease in older adults.

Provided are an antibody having effective neutralizing activity against RSV or an antigen-binding fragment thereof. The provided anti-RSV antibody or antigen-binding fragment thereof can be used as a drug for treating or preventing RSV infection or symptoms related to RSV infection. The provided RSV antibody, after humanization, can bind RSV-F protein with high affinity. In addition, experiments show that it is significantly better than palivizumab at providing protection against RSV challenge.

Provided are stable pre-fusion respiratory syncytial virus (RSV) F proteins. Also provided are immunogenic compositions comprising RSV F proteins and uses thereof for the prevention and / or treatment of RSV infection. Also provided are nucleic acids encoding the stable pre-fusion RSV F proteins.

This invention relates to the application of methyltransferase inhibitors as adjuvants for respiratory syncytial virus (RSV) vaccines and allergy vaccines. Methyltransferase inhibitors, as adjuvants for RSV vaccines or allergy vaccines, can target and regulate the antigen presentation function of vaccine-induced memory dendritic cells (DCs), thereby regulating the balance of T cell responses and balancing the dominant Th2 and / or Th17 cellular immune responses induced by RSV vaccines or allergy vaccines. This allows the vaccine recipient to develop a balanced immune memory, providing protection while preventing the occurrence of vaccine-enhanced inflammatory diseases when RSV infection or allergen stimulation occurs, thus being both safe and effective.

The application of OsFabF gene in resistance to rice stripe virus, the application relates to the technical field of rice disease resistance breeding. The application uses a CRISPR / Cas9 gene editing system to design sgRNA targeting a specific functional region of an endogenous OsFabF gene in rice, to precisely edit the region, thereby obtaining a mutant with a functionally deficient OsFabF. The editing preferably results in a frame shift mutation or a premature stop codon, to obtain a truncated OsFabF protein mutant. Experiments show that the rice mutant plant obtained in this way exhibits significantly enhanced resistance to RSV infection, reduced virus accumulation and reduced disease symptoms. The application provides an effective gene target and breeding material for cultivating new rice varieties resistant to rice stripe virus.